Patients with very early axial spondyloarthritis (axSpA) who started a first TNF inhibitor within 1 year of the onset of back pain did not have better 1-year clinical outcomes or longer drug retention ...

Exposure to TNF inhibitors was associated with a reduced risk for new-onset depression among patients with ankylosing spondylitis. Tumor necrosis factor (TNF) inhibitor therapy is associated with a ...

Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...

Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

AbbVie reported that its JAK inhibitor Rinvoq showed superior efficacy to its TNF inhibitor Humira in rheumatoid arthritis patients who had not responded to prior TNF therapy. The phase 3b/4 ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U.S. military veterans, a new study ...

Please provide your email address to receive an email when new articles are posted on . “Although several prior studies have examined infection risk in children exposed to biologics in utero, the ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Drug retention was similar with second-line IL-17 inhibitors and TNF inhibitors in patients with axial spondyloarthritis.